News

News Subscription

Jan 15. 2024
Basilea announces acquisition of preclinical antibiotics program from Spexis
Read more
Download
Jan 05. 2024
Basilea provides portfolio status update
Read more
Download
Dec 20. 2023 / Ad hoc announcement
Basilea announces accelerated loan repayment
Read more
Download
Dec 11. 2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
Read more
Download
Nov 20. 2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
Read more
Download
Nov 13. 2023 / Ad hoc announcement
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
Read more
Download
Oct 31. 2023 / Ad hoc announcement
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
Read more
Download
Oct 19. 2023 / Ad hoc announcement
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
Read more
Download
Oct 17. 2023
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
Read more
Download
Oct 02. 2023 / Ad hoc announcement
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
Read more
Download